Barinthus Biotherapeutics plc (BRNS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has a cash flow conversion efficiency ratio of -0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($84.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Barinthus Biotherapeutics plc's balance sheet to measure how much of total assets are equity-financed.
Barinthus Biotherapeutics plc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Barinthus Biotherapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Barinthus Biotherapeutics plc (BRNS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Barinthus Biotherapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sungwoo Electronics Co. Ltd
KQ:081580
|
0.042x |
|
Compugates Holdings Bhd
KLSE:5037
|
0.040x |
|
Aligos Therapeutics Inc
NASDAQ:ALGS
|
-0.728x |
|
Inventec Besta Co Ltd
TW:8201
|
-0.006x |
|
aXichem AB
ST:AXIC-A
|
-0.034x |
|
Klaria Pharma Holding AB
ST:KLAR
|
0.004x |
|
Maniker
KO:027740
|
-0.041x |
|
Scandinavian Enviro Systems AB
ST:SES
|
-0.116x |
Annual Cash Flow Conversion Efficiency for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Barinthus Biotherapeutics plc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Barinthus Biotherapeutics plc (BRNS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $130.13 Million | $-28.94 Million | -0.222x | +18.34% |
| 2023-12-31 | $187.00 Million | $-50.92 Million | -0.272x | -358.95% |
| 2022-12-31 | $243.20 Million | $-14.43 Million | -0.059x | +54.01% |
| 2021-12-31 | $252.56 Million | $-32.58 Million | -0.129x | -103.68% |
| 2020-12-31 | $-3.15 Million | $-11.03 Million | 3.504x | +312.44% |
| 2019-12-31 | $-22.08 Million | $-18.76 Million | 0.850x | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more